Last reviewed · How we verify
Medrifar (MEDRYSONE)
Medrifar (MEDRYSONE) is a corticosteroid medication originally developed by Allergan and currently owned by the same company. It targets the glucocorticoid receptor and is used to treat various ocular inflammatory conditions. Medrifar is a small molecule medication that has been FDA-approved since 1969 for indications such as allergic conjunctivitis and post-op ocular inflammation. The medication is off-patent, meaning it is no longer protected by active patents, and there are currently no generic manufacturers. As a result, its commercial status is uncertain.
At a glance
| Generic name | MEDRYSONE |
|---|---|
| Sponsor | AbbVie |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1969 |
Approved indications
- Allergic conjunctivitis
- Corneal abrasion
- Corneal ulcer
- Cyclitis
- Herpes zoster keratitis
- Iridocyclitis
- Iritis
- Post-Op Ocular Inflammation
- Punctate keratopathy
- Rosacea
- Uveitis
Common side effects
- Elevation of intraocular pressure (IOP)
- Transient burning and stinging upon instillation
- Ocular irritation
- Posterior subcapsular cataract formation
- Delayed wound healing
- Keratitis
- Conjunctivitis
- Corneal ulcers
- Mydriasis
- Conjunctival hyperemia
- Loss of accommodation
- Ptosis
Serious adverse events
- Development of glaucoma
- Optic nerve damage
- Systemic hypercorticoidism
- Acute anterior uveitis
- Perforation of the globe
- Secondary ocular infection (bacterial)
- Secondary ocular infection (fungal)
- Secondary ocular infection (viral)
- Fungal invasion of cornea
Key clinical trials
- InPART RX - Epicenters (NA)
- Reducing Overuse of Antibiotics at Discharge Home (NA)
- Coagulation in Acute Aortic Dissection (NA)
- Project Gnosis: the Neurophysical and Psychosocial Health Outcomes of Tai Chi for Older Adults with Cognitive Concerns or Mild Cognitive Impairment (NA)
- EINTER PROGRAM in Spinal Cord Injury Patients (NA)
- Hexoskin Medical System - ECG Performance Testing
- An Implementation Research of Simulation Based Mentorship Program (NA)
- Miniaturized Extracorporeal Circulation Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Medrifar CI brief — competitive landscape report
- Medrifar updates RSS · CI watch RSS
- AbbVie portfolio CI